MwanzoFTRE • NASDAQ
add
Fortrea Holdings Inc
$ 19.73
Baada ya Saa za Kazi:(0.00%)0.00
$ 19.73
Imefungwa: 22 Nov, 16:16:10 GMT -5 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 19.50
Bei za siku
$ 19.18 - $ 20.14
Bei za mwaka
$ 16.53 - $ 41.02
Thamani ya kampuni katika soko
1.77B USD
Wastani wa hisa zilizouzwa
1.32M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
(USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Mapato | 674.90M | -5.45% |
Matumizi ya uendeshaji wa biashara | 157.50M | 21.53% |
Mapato halisi | -27.90M | -99.29% |
Kiwango cha faida halisi | -4.13 | -110.71% |
Mapato kwa kila hisa | 0.23 | -4.17% |
EBITDA | 12.00M | -72.22% |
Asilimia ya kodi ya mapato | 48.32% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
(USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 105.30M | -4.01% |
Jumla ya mali | 3.66B | -15.13% |
Jumla ya dhima | 2.15B | -18.01% |
Jumla ya hisa | 1.51B | — |
hisa zilizosalia | 89.70M | — |
Uwiano wa bei na thamani | 1.16 | — |
Faida inayotokana na mali | -0.64% | — |
Faida inayotokana mtaji | -0.85% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
(USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Mapato halisi | -27.90M | -99.29% |
Pesa kutokana na shughuli | -2.40M | -226.32% |
Pesa kutokana na uwekezaji | -8.10M | -400.00% |
Pesa kutokana na ufadhili | -14.00M | -81.82% |
Mabadiliko halisi ya pesa taslimu | -20.90M | -309.80% |
Mtiririko huru wa pesa | -19.35M | -269.37% |
Kuhusu
Fortrea Holdings Inc. is a contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in 90 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries.
Its primary business is handling all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, and post-approval services. It handles regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. It focuses on oncology, central nervous system and neurodegenerative, rare diseases, and cell and gene therapies. In the five years ending in 2023, it conducted more than 5,850 clinical trials involving over 1 million subjects. It also conducted over 600 studies for medical device companies.
The company is one of the largest participants in the international primate trade and has been criticized for its animal testing practices, most specifically animal testing on non-human primates. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
Apr 1996
Tovuti
Wafanyakazi
15,500